Dr Marcus Remer is a Consultant Medical Oncologist at Hampshire Hospitals NHS Foundation Trust, specialising in the treatment of breast cancer, lung cancer, mesothelioma and other thoracic malignancies. He is committed to delivering personalised cancer care and has particular expertise in precision oncology, immunotherapy and molecularly targeted treatments.

Dr Remer graduated from the University of Bristol in 2006 with degrees in Medicine and Surgery and a BSc in Pharmacology. Following early clinical training in Bristol, Bath and London, he completed Core Medical Training and gained Membership of the Royal College of Physicians. During this time, he developed a strong interest in oncology through appointments at Mount Vernon Cancer Centre and St Luke's Cancer Centre before undertaking specialist Medical Oncology training at University Hospital Southampton.

Alongside his clinical training, Dr Remer was awarded Cancer Research UK funding to undertake a PhD in Cancer Immunotherapy. His research focused on novel immunotherapy approaches and was published in leading peer-reviewed scientific journals. He has subsequently authored numerous scientific publications and book chapters within the field of oncology.

Since his appointment as a Consultant Medical Oncologist in 2019, Dr Remer has developed a specialist practice treating patients with both early-stage and advanced cancers. He has a particular interest in ensuring patients have access to the latest advances in cancer treatment, including immunotherapy, targeted therapies and comprehensive genomic profiling to help guide personalised treatment decisions.

Dr Remer is recognised for his expertise in precision medicine and molecular diagnostics. He founded the regional Wessex Lung Cancer Molecular Tumour Board, supporting clinicians across the region in the use of advanced molecular testing and circulating tumour DNA ("liquid biopsy") technologies. He has also served as the regional clinical lead for a national NHS England improvement programme aimed at expanding access to early molecular testing in lung cancer, helping improve access to targeted treatments and patient outcomes.

In addition to his clinical work, Dr Remer is actively involved in research, education and service development. He lectures on the MSc Oncology programme at the Institute of Cancer Research in London and contributes to specialist national multidisciplinary cancer services as a member of the National Peritoneal Mesothelioma Multidisciplinary Team.

Dr Remer is committed to providing clear, compassionate and evidence-based care, ensuring that patients understand their diagnosis and treatment options and feel supported throughout their cancer journey. He offers face-to-face, video and telephone consultations.

• Breast Cancer
• Lung Cancer
• Mesothelioma and Thoracic Cancers
• Personalised Cancer Treatment
• Immunotherapy and Targeted Cancer Treatments
• Advanced Molecular and Genetic Testing
• Precision Medicine and Treatment Planning
• Early and Advanced Stage Cancer Care

• British Thoracic Oncology Group (BTOG)
• UK Breast Cancer Group (UKBCG)
• European Society of Medical Oncology (ESMO)
• American Society of Clinical Oncology (ASCO)
• International Association for the Study of Lung Cancer (IASLC)
• British Medical Association (BMA)